Johnson & Johnson’s Janssen Pharmaceuticals and three other drug companies have agreed to move forward on a $26 billion global opioid settlement, the second largest multistate agreement in U.S. history.

The deal, announced July 21, was contingent on a certain percentage of states, cities and counties participating. Today was the deadline for the defendants to decide whether the participation rate was enough to resolve the vast majority of more than 4,000 opioid claims brought by governments across the country.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]